Dishman Pharmaceuticals & Chemicals, a manufacturer of active ingredients, announced that the company's Bavla facility was successfully inspected by the US FDA in July, 2016, which was intimated to the stock exchanges on July 09, 2016.

In this regard, the company has received the Establishment Inspection Report (EIR) from the US FDA for this facility on February 01, 2017.

Thus, the company's facilities in Bavla, Naroda and Switzerland continue to be approved by the US FDA.

Shares of the company gained Rs 7.15, or 3.14%, to trade at Rs 235.10. The total volume of shares traded was 53,114 at the BSE (9.38 a.m., Thursday).